Societal and individual burden of illness among fibromyalgia patients in France: Association between disease severity and OMERACT core domains

Table 6 Annual costs (2008 Euros) per FM patient, and by FM severity

Resource Utilization Cost	Total (n = 88)		Mild (n = 17)		Moderate (n = 33)		Severe (n = 38)
	Mean (SD)	Median	Mean (SD)	Median	Mean (SD)	Median	Mean (SD)	Median	P -value ^a
Direct Medical Costs to Payer^b
Physician Visits	259 (163)	264	271 (118)	264	219 (112)	264	288 (208)	264
Diagnostic Tests	14 (38)	0	26 (61)	0	7 (20)	0	13 (37)	0
Prescription Medications	245 (345)	107	153 (207)	43	213 (312)	102	314 (409)	144
Hospitalizations	104 (972)	0	0 (0)	0	276 (1,587)	0	0 (0)	0
Direct Medical Costs to Patient^c	186 (425)	0	113 (256)	0	233 (448)	0	179 (467)	0
Total Direct Medical Costs to Society	808 (1,215)	540	564 (440)	528	949 (1,842)	504	794 (636)	595	0.434
Direct Non-Medical Cost to Patient^c
Professional services for ADL	103 (501)	0	93 (274)	0	108 (428)	0	103 (633)	0
Total Indirect Costs to Society^c
Lost productivity	6,990 (14,561)	0	4,816 (12,433)	0	5,576 (12,736)	0	9,190 (16,808)	0
Total Direct and Indirect Costs to Society	7,900 (14,868)	616	5,473 (12,852)	610	6,633 (13,498)	528	10,087 (16,785)	890	0.185

Extrapolated from 4-week patient-reported data and 3-month clinical case report form data
^aKruskal-Wallis test.
^bBased on unit cost and data reported in Clinical case report form.
^cBased on patient-reported data from study.
ADL: activities of daily living

ISSN: 1471-2474